WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Sugar molecules as a target in cancer therapy

Details
Research
07 November 2022
Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism can be neutralized.

The immune system is actually extremely well equipped to get rid of abnormal cells.

Read more ...

Study reveals vaccine confidence declined considerably during COVID-19 pandemic

Details
Research
07 November 2022
A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic.

Researchers from the University of Portsmouth carried out two anonymous surveys in the winters of 2019 and 2022 to investigate people's attitudes towards vaccinations and the factors that might underpin hesitancy and refusal.

Read more ...

New insights on antibody responses to Omicron variants

Details
Research
31 October 2022
Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research question. The answers could guide strategies to continue to subdue the COVID pandemic, even as the coronavirus regains ground.
Read more ...

The origin-of-life molecule, a key to cancer research

Details
Research
28 October 2022
RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cancer. Recent advances in research, such as those published by the research team of Daniel Gómez Cabello at the University of Seville, propose this compound as a therapeutic target for developing tailored strategies for treating cancer.
Read more ...

Ancient viral DNA in human genome guards against infections

Details
Research
27 October 2022
Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new research.

The paper, "Evolution and Antiviral Activity of a Human Protein of Retroviral Origin," published in Science, provides proof of principle of this effect.

Read more ...

Fighting tumors with magnetic bacteria

Details
Research
26 October 2022
Scientists around the world are researching how anti-cancer drugs can most efficiently reach the tumours they target. One possibility is to use modified bacteria as "ferries" to carry the drugs through the bloodstream to the tumours. Researchers at ETH Zurich have now succeeded in controlling certain bacteria so that they can effectively cross the blood vessel wall and infiltrate tumour tissue.
Read more ...

Novel derivative of "love hormone" oxytocin improves cognitive impairment in Alzheimer's

Details
Research
24 October 2022
The cognitive decline and memory loss observed in Alzheimer's disease (AD) is attributed to the accumulation of β-amyloid protein (Aβ), which impairs neural function in the brain. Experimentation has shown that oxytocin, a peptide hormone primarily responsible for parturition, bonding, and lactation, also regulates cognitive behavior in the rodent central nervous system (CNS).
Read more ...

More Pharma News ...

  1. Why late-night eating leads to weight gain, diabetes
  2. UCLA researchers identify a gene as a potential target in treatment-resistant brain cancer glioblastoma multiforme
  3. Protein IDs, drug candidates, show promise for COVID science
  4. A new AI model can accurately predict human response to novel drug compounds
  5. Possible target for treating and preventing osteoarthritis found in little-studied protein
  6. Experimental cancer drug could be effective in treating idiopathic pulmonary fibrosis
  7. Making pharmacy more sustainable
  • Start
  • Prev
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next
  • End

Business & Industry

  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
  • AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge

Research & Development

  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer
  • Engineered bacteria find tumors, then alert the authorities
  • First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Research
  4. Sugar molecules as a target in cancer therapy

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.